- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.2: 4 residues within 4Å:- Chain C: N.106, N.118, Y.135, D.290
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.11: 5 residues within 4Å:- Chain C: N.355, S.357
- Ligands: NAG-NAG-BMA.10, NAG-NAG-BMA.10, NAG-NAG-BMA.14
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.16: 4 residues within 4Å:- Chain E: N.106, N.118, Y.135, D.290
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.25: 5 residues within 4Å:- Chain E: N.355, S.357
- Ligands: NAG-NAG-BMA.24, NAG-NAG-BMA.24, NAG-NAG-BMA.28
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.30: 4 residues within 4Å:- Chain F: N.106, N.118, Y.135, D.290
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.39: 5 residues within 4Å:- Chain F: N.355, S.357
- Ligands: NAG-NAG-BMA.38, NAG-NAG-BMA.38, NAG-NAG-BMA.42
No protein-ligand interaction detected (PLIP)- 24 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA.4: 6 residues within 4Å:- Chain C: E.62, N.204, T.206, P.208, S.244, H.321
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.6: 3 residues within 4Å:- Chain C: N.246, T.248, N.249
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.7: 6 residues within 4Å:- Chain C: Q.263, N.265, V.302, S.303, R.412
- Ligands: NAG-NAG-BMA.9
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.9: 8 residues within 4Å:- Chain C: N.265, T.267, H.299, N.301, S.381, T.383, R.412
- Ligands: NAG-NAG-BMA.7
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.10: 6 residues within 4Å:- Chain C: N.332, S.333, N.355, S.357
- Ligands: NAG-NAG-BMA-MAN-MAN.11, NAG-NAG-BMA-MAN-MAN.11
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.12: 4 residues within 4Å:- Chain C: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.5
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.13: 5 residues within 4Å:- Chain C: Q.100, S.120, F.121, N.122, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.14: 4 residues within 4Å:- Chain C: G.358, N.361
- Ligands: NAG-NAG-BMA-MAN-MAN.11, NAG-NAG-BMA-MAN-MAN.11
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.18: 6 residues within 4Å:- Chain E: E.62, N.204, T.206, P.208, S.244, H.321
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.20: 3 residues within 4Å:- Chain E: N.246, T.248, N.249
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.21: 6 residues within 4Å:- Chain E: Q.263, N.265, V.302, S.303, R.412
- Ligands: NAG-NAG-BMA.23
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.23: 8 residues within 4Å:- Chain E: N.265, T.267, H.299, N.301, S.381, T.383, R.412
- Ligands: NAG-NAG-BMA.21
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.24: 6 residues within 4Å:- Chain E: N.332, S.333, N.355, S.357
- Ligands: NAG-NAG-BMA-MAN-MAN.25, NAG-NAG-BMA-MAN-MAN.25
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.26: 4 residues within 4Å:- Chain E: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.19
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.27: 5 residues within 4Å:- Chain E: Q.100, S.120, F.121, N.122, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.28: 4 residues within 4Å:- Chain E: G.358, N.361
- Ligands: NAG-NAG-BMA-MAN-MAN.25, NAG-NAG-BMA-MAN-MAN.25
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.32: 6 residues within 4Å:- Chain F: E.62, N.204, T.206, P.208, S.244, H.321
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.34: 3 residues within 4Å:- Chain F: N.246, T.248, N.249
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.35: 6 residues within 4Å:- Chain F: Q.263, N.265, V.302, S.303, R.412
- Ligands: NAG-NAG-BMA.37
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.37: 8 residues within 4Å:- Chain F: N.265, T.267, H.299, N.301, S.381, T.383, R.412
- Ligands: NAG-NAG-BMA.35
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.38: 6 residues within 4Å:- Chain F: N.332, S.333, N.355, S.357
- Ligands: NAG-NAG-BMA-MAN-MAN.39, NAG-NAG-BMA-MAN-MAN.39
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.40: 4 residues within 4Å:- Chain F: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.33
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.41: 5 residues within 4Å:- Chain F: Q.100, S.120, F.121, N.122, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA.42: 4 residues within 4Å:- Chain F: G.358, N.361
- Ligands: NAG-NAG-BMA-MAN-MAN.39, NAG-NAG-BMA-MAN-MAN.39
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.5: 13 residues within 4Å:- Chain C: S.179, E.181, P.182, V.224, L.231, N.232, R.274, N.346, G.348, C.413, V.414, S.415
- Ligands: NAG-NAG-BMA.12
2 PLIP interactions:2 interactions with chain C- Hydrogen bonds: C:E.181, C:V.414
NAG-NAG-BMA-MAN-MAN-MAN.19: 13 residues within 4Å:- Chain E: S.179, E.181, P.182, V.224, L.231, N.232, R.274, N.346, G.348, C.413, V.414, S.415
- Ligands: NAG-NAG-BMA.26
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:E.181, E:V.414
NAG-NAG-BMA-MAN-MAN-MAN.33: 13 residues within 4Å:- Chain F: S.179, E.181, P.182, V.224, L.231, N.232, R.274, N.346, G.348, C.413, V.414, S.415
- Ligands: NAG-NAG-BMA.40
2 PLIP interactions:2 interactions with chain F- Hydrogen bonds: F:E.181, F:V.414
- 21 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.43: 1 residues within 4Å:- Chain A: N.100
Ligand excluded by PLIPNAG.44: 2 residues within 4Å:- Chain A: N.107, E.110
Ligand excluded by PLIPNAG.45: 3 residues within 4Å:- Chain A: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.46: 1 residues within 4Å:- Chain B: N.100
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain B: N.107, E.110
Ligand excluded by PLIPNAG.48: 3 residues within 4Å:- Chain B: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain C: N.58
- Chain G: T.58
Ligand excluded by PLIPNAG.50: 1 residues within 4Å:- Chain C: N.107
Ligand excluded by PLIPNAG.51: 1 residues within 4Å:- Chain C: N.308
Ligand excluded by PLIPNAG.52: 1 residues within 4Å:- Chain C: N.324
Ligand excluded by PLIPNAG.53: 1 residues within 4Å:- Chain D: N.100
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain D: N.107, E.110
Ligand excluded by PLIPNAG.55: 3 residues within 4Å:- Chain D: E.123, N.126, Y.127
Ligand excluded by PLIPNAG.56: 2 residues within 4Å:- Chain E: N.58
- Chain I: T.58
Ligand excluded by PLIPNAG.57: 1 residues within 4Å:- Chain E: N.107
Ligand excluded by PLIPNAG.58: 1 residues within 4Å:- Chain E: N.308
Ligand excluded by PLIPNAG.59: 1 residues within 4Å:- Chain E: N.324
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain F: N.58
- Chain K: T.58
Ligand excluded by PLIPNAG.61: 1 residues within 4Å:- Chain F: N.107
Ligand excluded by PLIPNAG.62: 1 residues within 4Å:- Chain F: N.308
Ligand excluded by PLIPNAG.63: 1 residues within 4Å:- Chain F: N.324
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Sastry, M. et al., Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization. J.Virol. (2023)
- Release Date
- 2023-04-19
- Peptides
- Envelope glycoprotein gp41: ABD
Envelope glycoprotein gp120: CEF
vFP53.02 Fab heavy chain: GIK
vFP53.02 Fab light chain: HJL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BD
FC
CE
GF
IG
DI
HK
JH
EJ
LL
K
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 24 x NAG- NAG- BMA: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 21 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Sastry, M. et al., Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization. J.Virol. (2023)
- Release Date
- 2023-04-19
- Peptides
- Envelope glycoprotein gp41: ABD
Envelope glycoprotein gp120: CEF
vFP53.02 Fab heavy chain: GIK
vFP53.02 Fab light chain: HJL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BD
FC
CE
GF
IG
DI
HK
JH
EJ
LL
K